Clene Announces Q1 2025 Financial Results and Progress on CNM-Au8 Program for ALS and MS

Clene announced progress on its CNM-Au8 program for ALS and MS, preparing for potential NDA submission, giving a competitive edge in the market.

This news matters as Clene's advancements in developing therapies for neurodegenerative diseases like ALS and MS could potentially lead to improved treatment options for patients. The company's progress towards potential FDA approval and positive clinical trial results signify a significant step forward in the field of neurodegenerative disease research.

Read More https://newsramp.com/curated-news/clene-announces-q1-2025-financial-results-and-progress-on-cnm-au8-program-for-als-and-ms/a6e28345fb7871fac5caf6041af2d166